Beyond these canonical TACC partners, next-generation sequencing has revealed a spectrum of noncanonical fusions (e.g., FGFR3-FASN, FGFR3-BAIAP2L1) in both primary and recurrent gliomas (Diaz et al., 2024; Gu et al., 2021). This evidence concerns the gene FGFR3 and central nervous system cancer.